share_log

康希諾生物：自願公告 - 重組肺炎球菌蛋白疫苗獲得I期臨床積極初步結果

CANSINOBIO: VOLUNTARY ANNOUNCEMENT - POSITIVE PRELIMINARY PHASE I CLINICAL RESULTS FOR PROTEIN-BASED PNEUMOCOCCAL VACCINE

Hong Kong Stock Exchange ·  Apr 21 06:19
Summary by Moomoo AI
康希諾生物股份公司（「康希諾生物」）於2024年4月21日宣布，其自主研發的重組肺炎球菌蛋白疫苗（PBPV）在I期臨床試驗中獲得積極的初步結果。該疫苗針對廣泛的肺炎球菌株提供保護，覆蓋率至少達98%，且生產工藝簡便，有助於質量控制和放大生產。臨床試驗包括18至49歲健康成人的隨機、雙盲、安慰劑對照Ia期試驗，以及50歲及以上成人的隨機、盲法、陽性對照Ib期試驗。試驗結果顯示，PBPV具有良好的安全性，未觀察到3級不良反應和特殊的安全性風險，且單劑接種能誘導顯著的結合抗體和功能性殺菌抗體應答。康希諾生物將根據I期試驗結果進行下一階段的研發工作評估和規劃。
康希諾生物股份公司（「康希諾生物」）於2024年4月21日宣布，其自主研發的重組肺炎球菌蛋白疫苗（PBPV）在I期臨床試驗中獲得積極的初步結果。該疫苗針對廣泛的肺炎球菌株提供保護，覆蓋率至少達98%，且生產工藝簡便，有助於質量控制和放大生產。臨床試驗包括18至49歲健康成人的隨機、雙盲、安慰劑對照Ia期試驗，以及50歲及以上成人的隨機、盲法、陽性對照Ib期試驗。試驗結果顯示，PBPV具有良好的安全性，未觀察到3級不良反應和特殊的安全性風險，且單劑接種能誘導顯著的結合抗體和功能性殺菌抗體應答。康希諾生物將根據I期試驗結果進行下一階段的研發工作評估和規劃。
Conchino Biologics Corporation (“Conchino Biobiology”) announced on 21 April 2024 that its independently developed recombinant pneumococcal protein vaccine (PBPV) obtained positive preliminary results in a Phase I clinical trial. The vaccine provides protection against a wide range of pneumococcal strains, with a coverage rate of at least 98% and an easy production process, helping to control quality and increase production. The clinical trial consisted of a randomized, double-blind, placebo-controlled Phase Ia trial in healthy adults aged 18 to 49, and a randomized, blind, positive-controlled Phase Ib trial in adults aged 50 and older. The trial results showed that PBPV has good safety, no Grade 3 adverse reactions and special safety risks are observed, and single dose vaccination induces significant combined antibody and functional bactericidal antibody responses. Conchinobiota will be evaluated and planned for the next phase of R&D based on the results of the Phase I trial.
Conchino Biologics Corporation (“Conchino Biobiology”) announced on 21 April 2024 that its independently developed recombinant pneumococcal protein vaccine (PBPV) obtained positive preliminary results in a Phase I clinical trial. The vaccine provides protection against a wide range of pneumococcal strains, with a coverage rate of at least 98% and an easy production process, helping to control quality and increase production. The clinical trial consisted of a randomized, double-blind, placebo-controlled Phase Ia trial in healthy adults aged 18 to 49, and a randomized, blind, positive-controlled Phase Ib trial in adults aged 50 and older. The trial results showed that PBPV has good safety, no Grade 3 adverse reactions and special safety risks are observed, and single dose vaccination induces significant combined antibody and functional bactericidal antibody responses. Conchinobiota will be evaluated and planned for the next phase of R&D based on the results of the Phase I trial.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more